The trial involved adults and adolescents aged 12 years and above with MOGAD, offering an open-label extension.
MOGAD, or myelin oligodendrocyte glycoprotein antibody-associated disease, is a rare disease in which the immune system ...
Satralizumab significantly reduces relapse risk in patients with relapsing MOGAD, according to phase 3 METEOROID trial results presented at AAN 2026.
Add Yahoo as a preferred source to see more of our stories on Google. Have you ever looked up at a “shooting star” and wondered what you’re actually seeing? The terms meteor, meteorite, and meteoroid ...
Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study ...
Hosted on MSN
First clinical trial in MOGAD meets primary endpoint
The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of ...
Meteoroid impacts represent one of the most dynamic interactions between extraterrestrial bodies and the Earth’s atmosphere. When meteoroids enter the atmosphere, they experience rapid deceleration ...
Meteoroid streams are coherent groups of debris originating primarily from cometary or asteroidal fragmentation, which travel through the Solar System along similar orbital paths. As Earth intersects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results